# A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Source: https://onco.cc/trials/nct06855771/  
OnCo record `nct06855771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BMS-986504 in non-small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) is a phase 2 interventional study registered as NCT06855771 by Bristol-Myers Squibb, with 130 participants planned, started 2025-09-09 and due to reach its primary completion in 2028-12-29. Interventions recorded: BMS-986504.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06855771
- Phase: 2
- Setting: A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies
- Sponsor: Bristol-Myers Squibb
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06855771: https://clinicaltrials.gov/study/NCT06855771

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06855771.json